Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.
Weight loss drugs
Novo Nordisk signs $285 million deal for a once-monthly GLP-1 receptor agonist
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease.
AI study shows GLP-1s could help prevent heart disease in millions
Dandelion Health used its new clinical AI marketplace to analyze real-world data, showing that GLP-1 drugs may help prevent cardiovascular disease (CVD) for a seven times larger population than previously researched.
Eli Lilly expands manufacturing facilities in Ireland with $1.8bn investment
With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion program in the company’s history.
Vaxess' Rachel Sha - 'own the seat at the table that you have and have confidence'
Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have confidence and answer hard questions.
Weight loss drug's trial results show promise protecting brain against dementia
Results from a phase 2b clinical trial in the UK have shown that Novo Nordisk’s GLP-1 drug liraglutide can protect the brain against dementia.